- Home
- BRBI vs ABEO Comparison
BRBI vs ABEO Comparison
Compare BRBI & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BRBI | ABEO |
|---|---|---|
| Founded | 2009 | 1974 |
| Country | Brazil | United States |
| Employees | 188 | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 293.2M | 320.3M |
| IPO Year | N/A | 2005 |
Fundamental Metrics
Financial Performance| Metric | BRBI | ABEO |
|---|---|---|
| Price | $11.50 | $6.93 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $20.00 |
| AVG Volume (30 Days) | 1.2K | ★ 1.5M |
| Earning Date | 05-08-2026 | 05-13-2026 |
| Dividend Yield | ★ 5.03% | N/A |
| EPS Growth | N/A | ★ 165.16 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,998,000.00 |
| Revenue This Year | N/A | $1,024.31 |
| Revenue Next Year | $17.24 | $145.42 |
| P/E Ratio | $11.72 | ★ N/A |
| Revenue Growth | N/A | ★ 258.18 |
| 52 Week Low | $10.90 | $4.00 |
| 52 Week High | $67.01 | $7.54 |
Technical Indicators
Market Signals| Indicator | BRBI | ABEO |
|---|---|---|
| Relative Strength Index (RSI) | 41.10 | 68.05 |
| Support Level | $10.90 | $4.85 |
| Resistance Level | $15.06 | N/A |
| Average True Range (ATR) | 0.21 | 0.32 |
| MACD | 0.02 | 0.12 |
| Stochastic Oscillator | 21.98 | 76.66 |
Price Performance
Historical ComparisonAbout BRBI BRBI BR Partners S.A. ADSs
BRBI BR Partners SA, formerly BR Advisory Partners Participacoes SA, is engaged in investing in other companies, domestic or foreign, as a partner, quota holder, or shareholder, and management of its assets. It has a single reportable segment being investment banking services, which are administered and managed according to the products offered. However, the company divides it's operations into the following business lines: (1) investment banking and capital markets, (2) treasury sales & structuring, (3) investments and wealth management and (4) capital remuneration.
About ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.